Do elevated plasma vasoactive intestinal polypeptide (VIP) levels cause small intestinal motor disturbances in humans?
Increased VIP plasma levels cause severe secretory diarrhea. Moreover, VIP is a major regulator of human intestinal motility. We hypothesized that VIP-mediated intestinal motility disturbances contribute to symptoms in elevated plasma VIP. Ten healthy volunteers were intubated twice with an orojejunal multilumen tube for duodenal manometry, jejunal perfusion of electrolyte and marker solution, and aspiration 10 and 40 cm more distally. All subjects randomly received intravenous infusion of saline and 300 pmol/kg x hr VIP for 5 hr. Results showed that VIP but not saline infusion induced netjejunal sodium secretion, watery diarrhea, and cardiovascular effects (P < 0.04). VIP did not alter intestinal motor activity or the mean duration of the interdigestive motility cycle or of phases I and II but nearly halved the duration of phase III (P = 0.0002). We conclude that increased plasma VIP markedly shortens human phase III activity without influencing other motility parameters. Hence, it is unlikely that VIP-mediated small intestinal motor disturbances cause symptoms in VIPOMA. Yet VIP may contribute to terminate phase III motility.
Keller
Jutta
J
Israelitic Hospital, Hamburg, Germany. keller@ik-h.de
Mueller-Wolf
Jan C
JC
Ahmadi-Simab
Keihan
K
Fibbe
Christiane
C
Rosien
Ulrich
U
Layer
Peter
P
D005769:Gastrointestinal Motility / Q000502:physiology*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000503:physiopathology; D014660:Vasoactive Intestinal Peptide / Q000097:blood*; D003969:Vipoma / Q000503:physiopathology
D014660:Vasoactive Intestinal Peptide
J Auton Pharmacol. 1991 Dec;11(6):353-64
1722215
Gastroenterology. 1998 Aug;115(2):370-80
9679042
Dig Dis Sci. 1995 Mar;40(3):678-84
7895565
Eur J Pharmacol. 1997 Aug 20;333(1):87-92
9311665
Aliment Pharmacol Ther. 1994 Oct;8(5):475-88
7865639
Am J Physiol. 1992 Apr;262(4 Pt 1):G690-4
1566850
Am J Physiol. 1995 Oct;269(4 Pt 1):G584-90
7485511
Am J Physiol Gastrointest Liver Physiol. 2001 Feb;280(2):G273-8
11208550
Scand J Gastroenterol. 1977;12(8):993-7
605359
Gastroenterology. 1977 Jul;73(1):23-7
324861
Dig Dis Sci. 1994 Dec;39(12 Suppl):73S-75S
7995221
Am J Physiol. 1996 Oct;271(4 Pt 1):G582-90
8897876
Gastroenterology. 1991 Jan;100(1):99-106
1983854
N Engl J Med. 1993 Oct 7;329(15):1073-8
8371728
Histol Histopathol. 1999 Oct;14(4):1119-34
10506928
Gut. 1984 Nov;25(11):1225-9
6149978
Am J Physiol. 1998 Nov;275(5 Pt 1):G979-83
9815027
Eur J Pharmacol. 1996 Nov 7;315(1):59-64
8960865
Gut. 1994 May;35(5):641-5
8200557
Acta Physiol Scand. 1998 Nov;164(3):317-23
9853020
Arch Physiol Biochem. 2001 Jul;109(3):246-51
11880929
J Clin Invest. 1977 Jun;59(6):1158-66
864008
Am J Physiol. 1992 Oct;263(4 Pt 1):E740-7
1415694
Eur J Gastroenterol Hepatol. 1996 Dec;8(12):1207-11
8980942
Am J Physiol. 1994 Jan;266(1 Pt 1):G31-9
8304456
Neurogastroenterol Motil. 1996 Dec;8(4):299-306
8959734
Neurogastroenterol Motil. 1999 Jun;11(3):235-41
10354348
Am J Dig Dis. 1976 Nov;21(11):957-62
984017
Eur J Pharmacol. 1997 Jun 11;328(2-3):217-27
9218704
J Surg Res. 1995 Jan;58(1):111-5
7830399
Neurogastroenterol Motil. 1997 Sep;9(3):143-50
9347469
Peptides. 1994;15(8):1373-6
7700839
Acta Physiol Scand. 1999 Feb;165(2):225-31
10090335
Am J Physiol. 1996 Sep;271(3 Pt 1):G433-7
8843766
Lancet. 1990 Jun 30;335(8705):1555-7
1972488
Gastroenterology. 1970 Mar;58(3):321-8
5437985
Am J Physiol. 1993 Feb;264(2 Pt 1):G334-40
8447417
J Appl Physiol (1985). 2002 Aug;93(2):592-600
12133869
Dig Dis Sci. 1998 Dec;43(12):2719-26
9881505
Clin Biochem. 2002 Nov;35(8):641-6
12498999
Dig Dis. 1991;9(6):389-95
1804579
Am J Physiol. 1998 Nov;275(5 Pt 1):G897-903
9815017